SCHEMBL4474918

SCHEMBL4474918

CC1CCN(c2nsc(N3CCNCC3)n2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.40
SMN1; SMN2 Q16637 4/20 0.40
KDM4E B2RXH2 4/20 0.40
TSHR P16473 3/20 0.40
HPGD P15428 3/20 0.40
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
MAPK1 P28482 1/20 0.40
HRH1 P35367 1/20 0.40
TDP1 Q9NUW8 2/20 0.39
USP2 O75604 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.38
CASP1 P29466 2/20 0.35
CASP4 P49662 1/20 0.35
CASP5 P51878 1/20 0.35
POLB P06746 2/20 0.34
CYP1A2 P05177 1/20 0.34
CASP7 P55210 1/20 0.34
HSD17B10 Q99714 1/20 0.34
GUSB P08236 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4482650 0.82 HRH1 (0.60) ALDH1A1SMN1; SMN2KDM4EHRH1TDP1
SCHEMBL13817552 0.81 HRH1 (0.42) ALDH1A1SMN1; SMN2KDM4EHPGDHRH1
SCHEMBL4483298 0.81 USP2 (0.61) ALDH1A1SMN1; SMN2KDM4EHRH1TDP1
SCHEMBL13035720 0.74 SMN1; SMN2 (0.46) ALDH1A1SMN1; SMN2KDM4ETSHRHPGD
SCHEMBL3150091 0.72 DPP4 (0.42) SMN1; SMN2KDM4EHRH1TDP1USP2
SCHEMBL26157096 0.69 ALDH1A1 (0.47) ALDH1A1KDM4ETSHRHPGDUSP2
SCHEMBL4463170 0.69 FAAH (0.63) ALDH1A1SMN1; SMN2TSHRCASP1HSD17B10
SCHEMBL16280659 0.68 TSHR (0.60) ALDH1A1SMN1; SMN2KDM4ETSHRHPGD
SCHEMBL3159834 0.68 ADRB1 (0.40) ALDH1A1SMN1; SMN2KDM4EHRH1TDP1
SCHEMBL3152112 0.68 ADRB1 (0.39) ALDH1A1SMN1; SMN2KDM4EHPGDHRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7541359-B2 N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase JANSSEN PHARMACEUTICA N.V. (BE) 2009-06-02 US disclosed
US-7541359-B2 N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase JANSSEN PHARMACEUTICA N.V. (BE) 2009-06-02 US disclosed
US-7541359-B2 N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase JANSSEN PHARMACEUTICA N.V. (BE) 2009-06-02 US disclosed
WO-2007005510-A1 N-HETEROARYLPIPERAZINYL UREAS AS MODULATORS OF FATTY ACID AMIDE HYDROLASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-01-11 WO disclosed
US-20070004741-A1 N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase APODACA RICHARD 2007-01-04 US disclosed
US-20070004741-A1 N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase APODACA RICHARD 2007-01-04 US disclosed
US-20070004741-A1 N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase APODACA RICHARD 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004741-A1 N-heteroarylpiperazinyl ureas as modulators of fatty acid amide hydrolase FAAH, FAAH2, CNR2 ALDH1A1 2389/4885SMN1; SMN2 1755/4885KDM4E 1399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.